Infield Minerals Corp. (TSXV:IN)

Canada flag Canada · Delayed Price · Currency is CAD
0.0400
0.00 (0.00%)
Feb 6, 2026, 1:18 PM EST
Market Cap1.95M -10.3%
Revenue (ttm)n/a
Net Income-340.10K
EPS-0.01
Shares Out48.70M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,100
Average Volume28,940
Open0.0400
Previous Close0.0400
Day's Range0.0400 - 0.0400
52-Week Range0.0200 - 0.0650
Beta1.07
RSI45.51
Earnings DateApr 24, 2026

About Infield Minerals

Infield Minerals Corp. engages in the acquisition, exploration, and evaluation of mineral resource properties in the United States. The company explores for gold and silver deposits. It also holds 100% interest in the Desperado property that consist of 80 lode mining claims covering an area of approximately 1,650 acres located in the Nye County, Nevada; and Kings Canyon property in the state of Utah. Infield Minerals Corp. is headquartered in Vancouver, Canada. [Read more]

Sector Materials
CEO Evandra Nakano
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol IN
Full Company Profile

Financial Performance

Financial Statements

News

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call December 17, 2025 7:01 PM ESTCompany ParticipantsEric Adams - President, CEO &...

7 weeks ago - Seeking Alpha

InMed Announces Results of 2025 Annual General and Special Meeting

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

7 weeks ago - Newsfile Corp

InMed Provides Update on BayMedica Commercial Business

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

2 months ago - Newsfile Corp

Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Shares of NVIDIA Corp (NASDAQ: NVDA) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and issued a strong revenue forecast for the cu...

2 months ago - Benzinga

What's Driving InMed's (INM) 22% After-Hours Surge?

InMed Pharmaceuticals Inc. (NASDAQ: INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50. Check out the current price of INM stock here . The stock closed Wednesday's regular sess...

2 months ago - Benzinga

InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success

InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success

2 months ago - GuruFocus

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vanc...

2 months ago - Newsfile Corp

InMed Pharmaceuticals GAAP EPS of -$0.44

3 months ago - Seeking Alpha

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...

3 months ago - Newsfile Corp

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...

4 months ago - Newsfile Corp

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop...

4 months ago - Newsfile Corp

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-rel...

4 months ago - Newsfile Corp

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of propri...

5 months ago - GlobeNewsWire

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

5 months ago - Newsfile Corp

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc....

7 months ago - Newsfile Corp

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...

8 months ago - Newsfile Corp

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...

8 months ago - Newsfile Corp

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to...

8 months ago - Newsfile Corp

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...

8 months ago - Newsfile Corp

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...

9 months ago - Newsfile Corp

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

1 year ago - Newsfile Corp

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and ...

1 year ago - Newsfile Corp

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, i...

1 year ago - Newsfile Corp

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile sho...

1 year ago - Newsfile Corp

InMed Announces Results of 2024 Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

1 year ago - Newsfile Corp